Karen Joynt Maddox, MD, MPH, explained the many ways cardiology's business models are starting to evolve. She also touched on a number of other topics, including AI and the power of prevention.

Heartflow has officially gone public after selling more than 19 million shares of common stock during an upsized IPO. The California medtech company, known for its AI-powered CCTA evaluations, is now being traded on Nasdaq under the symbol HTFL.

Cardiologist compensation in the United States is experiencing slow, but steady growth. How does it compare to other specialties? 

New Hampshire-based Conformal Medical plans on using the funds to enroll more patients into an ongoing clinical trial. 

"We cannot accept a system where only those with means can benefit from life-changing drugs. We are a wealthy nation that spends trillions on healthcare. We must ensure that income and wealth do not determine access," explained JACC Editor-in-Chief Harlan M. Krumholz, MD.

The interventional cardiologist was accused of prescribing a variety of drugs to his family and friends, but then picking them up himself for his own personal use. This settlement officially resolves those allegations. 

Ultromics plans to use the new funds to help expand its presence throughout the United States. In addition, the company is focused on developing additional AI-enabled software offerings.

The first coronary DCB to gain FDA approval just received an additional reimbursement that could improve patient access. 

The tricuspid valve has been at the center of several key policy shifts in recent years. In fact, Medicare now covers both T-TEER and TTVR when performed with FDA-approved devices. We spoke to interventional cardiologist Jason H. Rogers, MD, to learn more about how this momentum has impacted patient care. 

Carmat is working to overcome financial struggles that forced it to suspend new device implants through the end of August. Even with its future in limbo, the company remains focused on moving forward.